Dyne Therapeutics - Meet the DM Drug Developers

Dyne’s Approach to Targeting DM1
Presenters include:
Josh Brumm, Chief Executive Officer;
Romesh Subramanian, PhD, Chief Scientific Officer;
Chris Mix, MD, Senior Vice President, Clinical Development; and
Molly White, Vice President, Medical Communications & Advocacy.
Learn more about Dyne Therapeutics at www.dyne-tx.com
Each month biotechnology, pharmaceutical and academic partners, large and small, working on treatments and a cure for myotonic dystrophy will sit down with our community to share their progress and answer your questions.
Find all our upcoming Meet the DM Drug Developers dates at www.myotonic.org/meet-dm-drug-developers
For more information on myotonic dystrophy, visit www.myotonic.org